Saturday 17 October 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.09
0.18
−5.50%
Follow ARDX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 3 | 3 | 3 | 5 | 6 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
3.45 | 3.57 | 10.66 | 8.15 | 11.35 | 76.55 | 90.24 | 38.60 | 10.94 | — |
Altman Z-Score |
1.12 | 1.20 | 2.76 | (3.07) | (8.32) | 0.30 | 1.41 | (2.48) | 7.54 | — |
Altman Z″-Score (non-manufacturers) |
(2.34) | (2.17) | (5.05) | (11.47) | (17.60) | (4.83) | 0.35 | (2.36) | 4.83 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
(2.40) | (1.05) | (0.58) | 3.66 | — | — | (2.17) | 1.37 | — | — |
P/Operating CF |
67.07 | 121.57 | (152.21) | 29.77 | (2.90) | (32.95) | (43.48) | (5.46) | 70.68 | — |
P/B ratio |
8.42 | 6.88 | 7.95 | 4.33 | 1.39 | 4.60 | 2.59 | 0.87 | 2.38 | — |
Price to Tangible BV |
8.42 | 6.88 | 7.95 | 4.33 | 1.39 | 4.60 | 2.59 | 0.87 | 2.38 | — |
EV/Sales |
3.36 | 3.36 | 9.80 | 6.62 | 3.96 | 58.63 | 53.44 | (7.00) | 6.52 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | — |
EV/Operating CF |
(32.26) | (25.00) | (13.59) | (4.93) | (0.26) | (5.45) | (3.75) | 0.26 | (3.04) | — |
EV/FCF |
(31.16) | (24.45) | (13.54) | (5.05) | (0.26) | (5.43) | (3.73) | 0.26 | (2.93) | — |
Quick Ratio |
3.80 | 3.95 | 4.09 | 2.01 | 2.22 | 6.56 | 11.17 | 9.77 | 8.10 | 10.46 |
Current Ratio |
4.31 | 4.58 | 4.88 | 2.34 | 2.53 | 6.85 | 11.34 | 9.95 | 8.38 | 10.62 |
Net Debt/EBITDA |
1.63 | 3.83 | 2.17 | 1.28 | 0.49 | 1.54 | 2.23 | 1.34 | 2.16 | 1.81 |
Debt/Assets |
40.44% | 34.62% | 16.74% | 23.06% | 28.02% | 25.20% | 19.25% | 26.84% | 0.00% | 0.00% |
Debt/Equity |
1.21 | 0.87 | 0.30 | 0.45 | 0.51 | 0.40 | 0.27 | 0.42 | 0.00 | 0.00 |
Asset Turnover |
0.87 | 0.91 | 0.51 | 0.31 | 0.06 | 0.03 | 0.02 | 0.02 | 0.23 | 0.00 |
Operating CF/Net income |
0.69 | 1.15 | 1.36 | 1.04 | 0.96 | 0.86 | 0.81 | 0.77 | 1.01 | 0.82 |
Capex/Depreciation |
(0.49) | (0.49) | (0.27) | 1.52 | (0.67) | (0.13) | (0.12) | (0.15) | (0.73) | (2.78) |
Interest Coverage |
(1.44) | (1.39) | (7.13) | (12.57) | (34.28) | (17.80) | (15.94) | (25.73) | — | — |
| (36.21%) | (23.01%) | (49.83%) | (74.28%) | (151.55%) | (60.31%) | (62.78%) | (71.57%) | (38.70%) | (74.42%) | |
| (13.14%) | (10.67%) | (27.10%) | (39.54%) | (90.00%) | (40.89%) | (42.85%) | (53.51%) | (34.68%) | (68.10%) | |
ROIC |
(24.37%) | (23.59%) | (122.29%) | (218.47%) | (1,214.94%) | 0.00% | 0.00% | 0.00% | (762.69%) | 0.00% |
Return on Tangible Assets |
(20.82%) | (13.97%) | (33.58%) | (75.32%) | (190.13%) | (56.07%) | (40.70%) | (55.58%) | (46.00%) | (58.00%) |
Average Days of Receivables |
64.38 | 63.13 | 64.61 | 54.12 | 18.15 | 0.00 | 51.84 | 711.94 | 93.82 | — |
Research and Development Expense of Revenue |
17.56% | 15.68% | 28.55% | 67.49% | 902.64% | 859.24% | 1,357.26% | 2,661.03% | 179.72% | 0.00% |
Selling, General and Administrative Expense of Revenue |
82.79% | 77.54% | 107.99% | 146.86% | 716.08% | 437.89% | 459.52% | 909.67% | 55.31% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.02% | 11.20% | 10.87% | 20.61% | 119.23% | 139.78% | 188.15% | 353.89% | 22.83% | 0.00% |
Graham Net Nets |
0.03 | 0.08 | 0.09 | 0.15 | 0.58 | 0.21 | 0.37 | 1.08 | 0.39 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(4.36%) | (3.22%) | (4.96%) | (17.91%) | (138.18%) | (16.23%) | (19.71%) | (90.50%) | (19.43%) | — |
Free Cash Flow Yield |
(3.13%) | (3.84%) | (6.79%) | (16.06%) | (134.71%) | (14.11%) | (15.86%) | (70.14%) | (20.34%) | — |
Revenue per Share |
1.69 | 1.42 | 0.57 | 0.33 | 0.10 | 0.08 | 0.08 | 0.05 | 0.89 | 0.00 |
Operating CF per Share |
(0.18) | (0.19) | (0.41) | (0.44) | (1.46) | (0.91) | (1.19) | (1.25) | (1.37) | (2.31) |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.01 | (0.02) | 0.00 | 0.00 | (0.01) | (0.05) | (0.12) |
Free Cash Flow per Share |
(0.18) | (0.19) | (0.41) | (0.43) | (1.48) | (0.91) | (1.19) | (1.26) | (1.42) | (2.43) |
Cash per Share |
1.10 | 1.06 | 0.84 | 0.78 | 1.12 | 2.08 | 3.84 | 2.99 | 2.82 | 5.01 |
Shareholders Equity per Share |
0.69 | 0.74 | 0.76 | 0.62 | 0.79 | 1.41 | 2.89 | 2.06 | 2.94 | 4.81 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.69 | 0.74 | 0.76 | 0.62 | 0.79 | 1.41 | 2.89 | 2.06 | 2.94 | 4.81 |
Free Cash Flow |
(43.97) | (45.82) | (90.06) | (68.30) | (154.42) | (81.76) | (76.81) | (70.58) | (67.54) | (97.40) |
Working Capital |
293.71 | 278.62 | 195.72 | 88.00 | 80.83 | 166.27 | 229.84 | 158.64 | 131.84 | 184.79 |
Capital Expenditures |
(1.49) | (1.01) | (0.34) | 1.74 | (1.87) | (0.32) | (0.32) | (0.31) | (2.35) | (4.87) |
Net Current Asset Value |
47.66 | 93.99 | 115.35 | 61.87 | 66.35 | 119.24 | 178.94 | 108.85 | 131.12 | 184.01 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | (0.03) | 0.18 | 0.04 | 0.06 | 0.12 | 0.06 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.40 | 1.38 | 1.28 | 0.94 | 1.19 | 1.31 | 0.81 | 0.36 | 0.40 | 0.19 |
Cash ROIC |
(6.93%) | (7.98%) | (22.46%) | (25.67%) | (63.99%) | (22.50%) | (15.86%) | (21.19%) | (24.72%) | (24.72%) |
Accounts Receivable Turnover |
6.29 | 8.37 | 8.36 | 12.67 | 16.13 | 0.00 | 1.81 | 0.33 | 6.28 | — |
Accounts Payable Turnover |
2.24 | 3.73 | 1.62 | 0.54 | 0.20 | 0.04 | 0.36 | 0.18 | 1.76 | 0.31 |
Inventory Turnover |
2.03 | 3.01 | 2.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
177.57 | 115.52 | 228.46 | 962.72 | 1,561.11 | 14,162.00 | 1,330.43 | 899.18 | 170.90 | 1,588.24 |
Days of Inventory on Hand |
163.73 | 152.86 | 255.33 | 290.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
64.78 | 39.87 | 14.88 | 4.12 | 0.63 | — | 2.92 | 7.94 | 6.69 | — |
Average Payables |
17.62 | 13.57 | 11.00 | 7.57 | 4.95 | 3.91 | 1.67 | 2.54 | 4.78 | 4.21 |
Average Inventory |
19.45 | 16.81 | 7.87 | — | — | — | — | — | — | — |
Average Assets |
468.68 | 366.67 | 243.82 | 169.99 | 175.74 | 230.67 | 221.56 | 170.62 | 185.52 | 165.04 |
Average Common Equity |
170.12 | 170.05 | 132.57 | 90.47 | 104.36 | 156.38 | 151.23 | 127.56 | 166.23 | 151.03 |
Columns are period end dates